Roivant/Roche: Did Pfizer Miss Out?
Merck/Prometheus Deal Changed TL1A Market Dynamics
Pfizer gave US rights to an asset to Roivant, which turned around and sold it to Roche for $7.1bn 10 months later. Pfizer says it’s content with the 25% stake it will receive. Roivant CEO Matt Gline also talked to Scrip about the sudden turnaround.
